ALT5 Sigma Signals Readiness as U.S. Stablecoin Legislation Passes into Law
ALT5 Sigma (NASDAQ:ALTS) has welcomed the signing of the GENIUS Act, a landmark U.S. law establishing regulatory framework for stablecoin issuance and oversight. The company, which has processed over $5 billion in cryptocurrency transactions serving more than 1,000 businesses globally, sees this legislation as a crucial development for the industry.
The announcement comes as stablecoins processed $27.6 trillion USD in on-chain transactions during 2024, exceeding the combined annual volumes of Visa and Mastercard. ALT5's infrastructure is designed to support compliant digital asset adoption at scale, positioning the company to benefit from the new regulatory clarity in an expanding global market.
ALT5 Sigma (NASDAQ:ALTS) ha accolto con favore la firma del GENIUS Act, una legge storica negli Stati Uniti che istituisce un quadro normativo per l'emissione e la supervisione delle stablecoin. L'azienda, che ha gestito oltre 5 miliardi di dollari in transazioni di criptovalute servendo pi霉 di 1.000 aziende a livello globale, considera questa legislazione un passo fondamentale per il settore.
L'annuncio arriva mentre le stablecoin hanno elaborato 27,6 trilioni di dollari USA in transazioni on-chain nel 2024, superando i volumi annuali combinati di Visa e Mastercard. L'infrastruttura di ALT5 猫 progettata per supportare l'adozione conforme degli asset digitali su larga scala, posizionando l'azienda per beneficiare della nuova chiarezza regolamentare in un mercato globale in espansione.
ALT5 Sigma (NASDAQ:ALTS) ha dado la bienvenida a la firma del GENIUS Act, una ley emblem谩tica en EE.UU. que establece un marco regulatorio para la emisi贸n y supervisi贸n de stablecoins. La compa帽铆a, que ha procesado m谩s de 5 mil millones de d贸lares en transacciones de criptomonedas atendiendo a m谩s de 1,000 empresas a nivel mundial, considera esta legislaci贸n como un avance crucial para la industria.
El anuncio se produce mientras las stablecoins procesaron 27.6 billones de d贸lares en transacciones on-chain durante 2024, superando los vol煤menes anuales combinados de Visa y Mastercard. La infraestructura de ALT5 est谩 dise帽ada para apoyar la adopci贸n conforme de activos digitales a gran escala, posicionando a la empresa para beneficiarse de la nueva claridad regulatoria en un mercado global en expansi贸n.
ALT5 Sigma (NASDAQ:ALTS)電� 鞎堨爼頇旐彁 氚滍枆 氚� 臧愲弲鞚� 鞙勴暅 攴滌牅 頂勲爤鞛勳泴韥ゼ 靾橂頃橂姅 氙戈淡鞚� 須嶊赴鞝侅澑 氩曥晥鞚� GENIUS Act 靹滊獏鞚� 頇橃榿頄堨姷雼堧嫟. 5鞏� 雼煬 鞚挫儊鞚� 鞎旐樃頇旐彁 瓯半灅毳� 觳橂Μ頃橂┌ 鞝� 靹戈硠 1,000臧� 鞚挫儊鞚� 旮办梾鞐� 靹滊箘鞀るゼ 鞝滉车頃� 鞚� 須岇偓電� 鞚� 氩曥晥鞚� 鞐呹硠鞐� 欷戩殧頃� 氚滌爠鞚措澕瓿� 氤搓碃 鞛堨姷雼堧嫟.
鞚措矆 氚滍憸電� 2024雲� 霃欖晥 鞎堨爼頇旐彁臧� 27.6臁� 雼煬 攴滊鞚� 鞓泊鞚� 瓯半灅毳� 觳橂Μ頃橂┌ Visa鞕� Mastercard鞚� 鞐瓣皠 瓯半灅霟夓潉 頃╈箿 瓴冸炒雼� 毵庫潃 瓯半灅毳� 旮半頃� 臧�鞖措嵃 鞚措（鞏挫鞀惦媹雼�. ALT5鞚� 鞚疙攧霛茧姅 雽�攴滊鞚� 攴滌爼鞚� 欷�靾橅晿電� 霐旍韯� 鞛愳偘 毂勴儩鞚� 歆�鞗愴晿霃勲 靹り硠霅橃柎, 頇曥灔 欷戩澑 旮�搿滊矊 鞁滌灔鞐愳劀 靸堧鞖� 攴滌牅 氇呿檿靹膘溂搿滊秬韯� 鞚挫澋鞚� 鞏混潉 靾� 鞛堧姅 鞙勳箻鞐� 鞛堨姷雼堧嫟.
ALT5 Sigma (NASDAQ:ALTS) a salu茅 la signature du GENIUS Act, une loi am茅ricaine majeure 茅tablissant un cadre r茅glementaire pour l'茅mission et la supervision des stablecoins. L'entreprise, qui a trait茅 plus de 5 milliards de dollars en transactions de cryptomonnaies au service de plus de 1 000 entreprises dans le monde, consid猫re cette l茅gislation comme une avanc茅e cruciale pour le secteur.
L'annonce intervient alors que les stablecoins ont trait茅 27,6 trillions de dollars en transactions on-chain en 2024, d茅passant les volumes annuels combin茅s de Visa et Mastercard. L'infrastructure d'ALT5 est con莽ue pour soutenir l'adoption conforme des actifs num茅riques 脿 grande 茅chelle, positionnant l'entreprise pour b茅n茅ficier de la nouvelle clart茅 r茅glementaire sur un march茅 mondial en expansion.
ALT5 Sigma (NASDAQ:ALTS) begr眉脽t die Unterzeichnung des GENIUS Act, eines bahnbrechenden US-Gesetzes, das einen regulatorischen Rahmen f眉r die Ausgabe und 脺berwachung von Stablecoins schafft. Das Unternehmen, das 眉ber 5 Milliarden US-Dollar an Kryptow盲hrungstransaktionen abgewickelt und mehr als 1.000 Unternehmen weltweit bedient hat, sieht diese Gesetzgebung als einen entscheidenden Fortschritt f眉r die Branche.
Die Ank眉ndigung erfolgt, w盲hrend Stablecoins im Jahr 2024 27,6 Billionen US-Dollar an On-Chain-Transaktionen verarbeiteten und damit die kombinierten Jahresvolumina von Visa und Mastercard 眉bertrafen. Die Infrastruktur von ALT5 ist darauf ausgelegt, die regelkonforme Einf眉hrung digitaler Verm枚genswerte in gro脽em Ma脽stab zu unterst眉tzen und positioniert das Unternehmen, um von der neuen regulatorischen Klarheit in einem wachsenden globalen Markt zu profitieren.
- Processed over $5 billion USD in cryptocurrency transactions to date
- Serves more than 1,000 businesses worldwide
- New regulatory framework provides legal clarity for operations
- Positioned to benefit from growing stablecoin market that processed $27.6T in 2024
- Regulatory compliance may increase operational costs
- New regulations could limit certain business activities
Insights
ALT5 Sigma is well-positioned to benefit from new stablecoin legislation that provides regulatory clarity in a fast-growing market.
The passage of the GENIUS Act represents a watershed moment for the stablecoin industry, creating the regulatory framework that institutional players have been waiting for. This legislation effectively removes a significant barrier to mainstream adoption by establishing clear rules for stablecoin issuers and service providers like ALT5 Sigma.
The timing is particularly significant when examining market dynamics. Stablecoins processed
ALT5's strategic positioning is noteworthy - they've built compliance-first infrastructure ahead of regulation, processing over
The legislation creates a dual impact: it legitimizes compliant operators like ALT5 while simultaneously raising the barrier to entry for newcomers who must now navigate complex regulatory requirements. For enterprises seeking blockchain payment solutions, providers with established compliance frameworks become significantly more attractive.
The market implications extend beyond direct stablecoin issuance - as companies with robust settlement infrastructure that can integrate with existing financial systems stand to capture significant value in cross-border payments, remittances, and institutional transaction settlement.
LAS VEGAS, NV / / July 18, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) ("ALT5 or the "Company"), a fintech company delivering blockchain-powered payment and trading infrastructure for global merchants and financial institutions, today welcomed the signing of the GENIUS Act, a landmark U.S. law establishing a regulatory framework for stablecoin issuance and oversight.
"We believe this legislation marks a turning point," said Peter Tassiopoulos, CEO of ALT5 Sigma. "With a clear legal foundation now in place, U.S. enterprises can finally build with confidence and unlock the transformative capabilities of blockchain."
ALT5 infrastructure has been designed from the start to support responsible, compliant digital asset adoption at scale for compliance-first deployments; aligned with the principles now being codified in law. The company sees this legislation as a critical step toward leveling the playing field for regulated actors while protecting the industry from bad actors and systemic risk.
Stablecoins processed a staggering during 2024, surpassing the combined annual volumes for Visa and Mastercard. Their role in cross-border payments, remittances, and on-platform settlement continues to grow, particularly among fintechs and institutional users seeking efficiency and transparency.
ALT5 has processed over
The company supports responsible regulation and welcomes ongoing efforts by U.S. policymakers to bring greater structure and transparency to the digital asset ecosystem.
As adoption accelerates, this regulatory clarity is expected to streamline ALT5's continued growth in an expanding global market.
To learn more about how ALT5 supports institutional stablecoin integration, visit .
About ALT5 Sigma Corporation
(NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets.
Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: "ALT5 Pay" and "ALT5 Prime." The company has processed over
ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
The Company is also advancing the separation of its biotech business, which will continue under "Alyea Therapeutics Corporation." Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.
Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Media/Investor Relations Contact
[email protected]
1-800-400-2247
SOURCE: ALT5 Sigma Corp
View the original on ACCESS Newswire
FAQ
What is the GENIUS Act and how does it affect ALT5 Sigma (ALTS)?
How much transaction volume has ALT5 Sigma (ALTS) processed?
What was the total stablecoin transaction volume in 2024?
How will the new stablecoin regulations impact ALT5 Sigma's business?
What is ALT5 Sigma's market position in the stablecoin infrastructure space?
